Anti-Viral CD8 Central Memory Veto Cells As a New Platform for CAR T Cell Therapy

Human anti-viral CD8 central memory veto T cells generated from CMV and EBV-positive donors were evaluated in a clinical trial at MD Anderson Cancer Centre.